First report of cohort 3 and mature survival data from the U31402-A-U102 study of HER3-DXd in EGFR-mutated NSCLC

Hidetoshi Hayashi,Helena A. Yu,Christina Baik,Dong-Wan Kim,Melissa L. Johnson,Makoto Nishio,James Chih-Hsin Yang,Wu-Chou Su,Kathryn A. Gold,Marianna Koczywas,Egbert F. Smit,Conor Steuer,Enriqueta Felip,Haruyasu Murakami,Sang-We Kim,Ben Kim, Xin Su,Yoshimi Tanaka,Pang-Dian Fan, Frederique Cantero

ANNALS OF ONCOLOGY（2023）

引用 0|浏览14

暂无评分

摘要

U31402-A-U102 is an ongoing study of HER3-DXd in NSCLC. Here, with a 23-month median follow-up, we present the first report of median overall survival (OS) for patients (pts) with EGFRm NSCLC after failure of prior EGFR TKI and platinum-based chemotherapy (PBC) treated with HER3-DXd 5.6 mg/kg IV Q3W. Other efficacy and safety measures are updated to include new data from cohort 3.

查看译文

关键词

mature survival data,nsclc,egfr-mutated

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要